UPDATE  – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

    NEXT STORY
    Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
    PREV STORY
    P23 Labs Opens First Overseas Location
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Vaccine Market (2020 to 2027) – by Technology, Indication, and End-use

    author_avatar
    NASDAQ Market News

    Outlook on the Pet Food $72 Billion Global Market to 2030 – Identify Growth Segments for Investment

    author_avatar
    NASDAQ Market News

    U.S. News & World Report Recognizes NYC Health + Hospitals/Coney Island as High Performing in Heart Failure

    Brooklyn, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- NYC Health + Hospitals/Coney Island announced ...

    author_avatar
    NASDAQ Market News